Full-Time

Medical Science Liaison

Pulmonary

Deadline 10/14/26
Sanofi

Sanofi

10,001+ employees

Global pharma company; vaccines and R&D

Compensation Overview

$146.3k - $211.3k/yr

Cambridge, MA, USA

Remote

Remote, non-office-based work with possible substantial national and international travel.

Bachelor's, Master's, PharmD, PhD, MD

Category
Medical, Clinical & Veterinary
Required Skills
Risk Management

Get referred to Sanofi

See people who can refer or advise you

Requirements
  • An advanced degree in a technical, scientific, or medical field, or a relevant life science degree such as Registered Nurse, Master of Science, Physician Assistant, or Nurse Practitioner.
  • At least 2 years of experience working with Type 2-driven respiratory diseases such as asthma and chronic obstructive pulmonary disease, related clinical experience, or immunology specialty experience.
  • A valid driver's license with a clean driving record and the ability to pass a complete background check.
  • The ability to drive a company car safely to daily meetings and appointments.
  • Previous pharmaceutical industry or Medical Science Liaison experience.
  • A clear understanding of medical practice, clinical decision-making, and healthcare systems related to patient care.
  • The ability to interpret key scientific data and translate it to meet educational and research needs.
  • An understanding of the design and execution of research studies.
  • Proficiency with digital tools.
  • Deep knowledge of local regulations and pharmaceutical-industry codes of practice, particularly requirements governing non-promotional activities.
  • Knowledge of relevant healthcare systems, the evolving medical landscape, regulatory and payer environments, public health, and industry trends.
Responsibilities
  • Engage external stakeholders in medical and scientific information exchanges through one-on-one interactions and group settings.
  • Use knowledge of relevant diseases, disease-management protocols, the healthcare environment, and competitors to articulate the medical and scientific value of products to external experts.
  • Establish long-term peer relationships with Key Opinion Leaders and other stakeholder partners.
  • Share approved medical, clinical, epidemiologic, and scientific information with stakeholders and answer questions within regulatory guidelines.
  • Engage stakeholders to understand healthcare policies and guidelines affecting clinical practice at local, state, regional, federal, or national levels.
  • Map, identify, profile, and prioritize stakeholders using defined systems in line with the therapeutic-area medical plan.
  • Plan territory and individual-stakeholder medical strategies and engagement plans using the Scientific Engagement Model.
  • Establish a Sanofi Medical presence at relevant scientific congresses and symposia.
  • Organize educational meetings or local scientific advisory boards when requested.
  • Support speaker training to provide continued scientific support in the field.
  • Respond to unsolicited requests for medical information about supported products and disease areas.
  • Collect feedback and reactions from multiple data sources and stakeholders.
  • Record and report insights and information using approved mechanisms and tools.
  • Evaluate published studies and stakeholder interactions to develop insights about market needs and external-stakeholder opinions and contribute to scientific messages, plans, strategy, systems, and product development.
  • Monitor emerging evidence in the disease area to support discussions with Key Opinion Leaders and other stakeholders.
  • Distribute relevant scientific and medical information and external insights to internal stakeholders.
  • Collaborate with Commercial Operations, Business Development, Regulatory, and other functions on diligence reviews, medical and safety evaluations, product positioning, lifecycle evidence planning, and compliance needs.
  • Contribute to materials for internal and external stakeholders in accordance with company and applicable federal and national policies.
  • Monitor disease epidemiology and support protocol development for long-term surveillance, compliance, pharmacovigilance, and effectiveness studies.
  • Identify data-collection opportunities during stakeholder interactions and report them through approved processes.
  • Monitor clinical-trial activity within the territory and suggest clinical-trial sites when requested.
  • Respond to unsolicited requests about investigator-sponsored studies and support submissions through appropriate internal processes.
  • Operate independently with minimal supervision in complex regulatory environments through in-person and digital channels from a remote, non-office-based environment.
  • Manage a base of approximately 50 stakeholders and maintain the stakeholder-engagement tracking database.
  • Plan daily stakeholder interactions and discussion points in accordance with Medical Affairs strategy.
  • Execute the defined Key Opinion Leader territory strategy and develop territory engagement plans aligned with medical strategy and company objectives.
  • Use approved scientific data during Key Opinion Leader interactions to advance understanding of the therapeutic area.
Desired Qualifications
  • Relevant immunology clinical experience in an immunology clinical environment may be considered.
  • The ability to deliver current scientific and evidence-based data to address educational and research needs.
  • Exemplary communication and presentation skills.
  • Experience working on multidisciplinary teams and managing a significant volume of projects.
  • The ability to listen actively, state expert opinions diplomatically, and respect differing positions.
  • The ability to plan, prioritize, and execute multiple responsibilities and projects.
  • Scientific expertise, including staying current on data, treatment trends, and professional developments and translating expert feedback into actionable insights.

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 sales rose 13.6%, while launches grew 49.6% and Dupixent 30.8%.
  • July 2026 FDA approval expanded Sarclisa across all U.S. myeloma indications.
  • Paulo Fontoura assumed R&D leadership on September 1, 2026, accelerating pipeline execution.

What critics are saying

  • Tolebrutinib’s FDA rejection on December 24, 2025 exposed severe liver-injury risk.
  • Dupixent lawsuits consolidated in New Jersey by June 2026 threaten label and damages exposure.
  • Sanofi’s insulin plant needed €400 million German aid on September 8, 2026, signaling supply fragility.

What makes Sanofi unique

  • Dupixent posted €4.17 billion Q1 2026 sales, dominating immunology globally.
  • Sanofi’s July 2026 Sarclisa Escena became the first cancer on-body injector treatment.
  • Sanofi secured Cenrifki EU approval in June 2026, advancing a differentiated MS franchise.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

La Croix
Sep 8th, 2026
EU approves $448M German subsidy to Sanofi for insulin production security

The European Commission has approved a €400 million subsidy from Germany to pharmaceutical company Sanofi to maintain its Frankfurt insulin production site. The Commission stated that without this aid, Sanofi would close the German facility, reducing insulin supply security across the European Economic Area. The subsidy aims to compensate Sanofi for costs related to a service of general economic interest, strengthening insulin supply resilience for German patients. In return, Sanofi must build a new insulin factory in Frankfurt by 31 December 2032 and guarantee minimum annual production of 1.1 tonnes until 2042. Sanofi is among the world's leading insulin producers. The company announced in 2024 a €1.3 billion investment in Frankfurt to construct a new complex replacing existing facilities.

StreetInsider
Aug 25th, 2026
Altesa BioSciences wins award for oversubscribed $75M Series B to advance COPD therapies

Atlanta-based Altesa BioSciences has won the 2026 Georgia Life Sciences Golden Helix Award for Deal of the Year, recognising its oversubscribed $75 million Series B financing round. The funding, led by Forbion with participation from Sanofi, Medicxi, Pitango, and Atlantic Partners, will advance the clinical-stage pharmaceutical company's lead therapy, vapendavir. Vapendavir is an investigational oral treatment for chronic lung diseases including COPD and asthma. The drug is currently being evaluated in the Phase 2b CARDINAL trial, which will enrol 900 COPD patients across the US and UK. The Georgia Research Alliance Venture Fund was an early investor in Altesa. The company's scientific founders previously helped develop molnupiravir, one of the earliest COVID-19 treatments.

Business Wire
Aug 13th, 2026
Epicrispr Biotechnologies Closes $90 Million Oversubscribed Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Epicrispr Biotechnologies Closes $90 Million Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Morningstar
Aug 12th, 2026
InduPro raises $77M Series B, doses first patient in Phase 1 trial of bispecific ADC for lung cancer

InduPro has closed a $77 million Series B financing round and dosed its first patient in a Phase 1 study of IDP-001, its lead oncology programme. The biotechnology company is developing IDP-001, a bispecific antibody-drug conjugate targeting EGFR and a novel tumour-associated proximity antigen, for treating advanced squamous non-small cell lung cancer and other solid tumours. The Column Group led the financing round, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective, Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company. Proceeds will support Phase 1 clinical development and early proof-of-concept data generation for IDP-001, whilst advancing InduPro's broader preclinical pipeline. InduPro uses a proximity-guided platform to map protein spatial relationships on cell surfaces for discovering selective co-target pairs.

FinancialContent
Jul 24th, 2026
Scribe Therapeutics prices upsized $129M IPO at top of range

Scribe Therapeutics, a clinical-stage biotechnology company developing in vivo CRISPR technologies, has priced its upsized initial public offering at $15.00 per share, the high end of its range. The company is offering 8,580,000 shares, expecting to raise $128.7 million in gross proceeds before fees and expenses. Scribe has also granted underwriters a 30-day option to purchase up to 1,287,000 additional shares. The shares are expected to begin trading on the Nasdaq Global Market on 24 July 2026 under the ticker symbol "SCTX", with the offering closing on 27 July 2026. Additionally, Scribe has agreed to sell 500,000 shares at the same price to Sanofi in a concurrent private placement. Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo Securities are serving as joint book-running managers.